海外の治験の状況「1」での検索結果
148件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- A clinical study involving previously untreated patients with haemophilia A to look at how safe an experimental replacement factor VIII protein (known as rFVIIIFc) is to take and how well it works to prevent and stop bleeds.
- Hemophilia A MedDRA version: 20.0 Level: LLT Classification code 10053753 Term: Hemophilia A without inhibitors System Organ Class: 100000004850 MedDRA version: 20.0 Level: LLT Classification code 10060612 Term: Hemophilia A System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Australia, Brazil, Canada, Denmark, France, Germany, Ireland, Italy, Netherlands, New Zealand, Poland, Spain, Sweden, United Kingdom, United States
- 2014-05-06
Authorised
- Safety and efficacy of fixed dose combination of Indapamide SR 1.5 mg / Amlodipine versus Valsartan / Amlodipine over 12-week of treatment in patients with uncontrolled essential hypertension after 1 month of treatment by Amlodipine 5 mg.
- Uncontrolled essential hypertension MedDRA version: 14.1 Level: PT Classification code 10015488 Term: Essential hypertension System Organ Class: 10047065 - Vascular disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Argentina, Brazil, Bulgaria, Hungary, Latvia, Lithuania, Mexico, Poland, Romania, Russian Federation, South Africa, Thailand, Turkey, Ukraine, United Kingdom, Vietnam
- 2013-04-09
Authorised
- Not available
- Familial Amyloid Polyneuropathy br>MedDRA version: 20.0 Level: LLT Classification code 10057949 Term: Familial amyloid polyneuropathy System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Argentina, Brazil, France, Germany, Italy, New Zealand, Portugal, Spain, United Kingdom, United States
- 2014-05-07
Authorised
- A Non-Interventional Study to Monitor the Survival Status of Patients that Discontinued from ISIS 420915-CS2 or ISIS 420915-CS3
- Familial Amyloid Polyneuropathy br>MedDRA version: 20.0 Level: LLT Classification code 10057949 Term: Familial amyloid polyneuropathy System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Argentina, Brazil, France, Germany, Italy, New Zealand, Portugal, Spain, United Kingdom, United States
- 2018-02-19
Authorised
- NA
- Gaucher disease MedDRA version: 14.0 Level: PT Classification code 10018048 Term: Gaucher's disease System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Canada, Chile, Israel, Italy, Mexico, Serbia, South Africa, Spain
- 2011-10-13
Authorised
- A Study Of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression during or After Aromatase Inhibitor Therapy
- WOMEN WITH ER-POSITIVE AND HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAS DIDEASE RECURRENCE OR PROGRESSION DURING OR AFTER AROMATASE INHIBITOR THERAPY MedDRA version: 17.1 Level: LLT Classification code 10070575 Term: Estrogen receptor positive breast cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Bulgaria, Canada, Colombia, Czech Republic, France, Germany, Greece, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Peru, Poland, Portugal, Romania, Russian Federation, Spain, Sweden, Turkey, United States
- 2015-01-12
Authorised
- A phase III, open-label, multiarm study to assess the efficacy of immunotherapy together with standard of care in patients diagnosed with extensive stage Small-Cell Lung Cancer
- First-line patients with extensive disease (Stage IV) small-cell lung cancer (SCLC) MedDRA version: 20.0 Level: PT Classification code 10041068 Term: Small cell lung cancer extensive stage System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Austria, Brazil, Bulgaria, China, Czech Republic, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Romania, Russian Federation, Slovakia, Spain, Taiwan, Turkey, Ukraine, United States
- 2017-01-26
Authorised
- A Study with an active treatment to Assess the Long-term Safety of Weekly Intravenous Product in Subjects with Pulmonary Emphysema due to Alpha1-Antitrypsin Deficiency
- Pulmonary Emphysema due to Alpha-1-Antitrypsin Deficiency MedDRA version: 19.0 Level: LLT Classification code 10014563 Term: Emphysema pulmonary System Organ Class: 100000004855 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
- Argentina, Australia, Brazil, Canada, Denmark, Estonia, France, Germany, New Zealand, Poland, Romania, Russian Federation, Spain, Sweden, United States
- 2016-01-29
Authorised
- A study evaluating the of safety and efficacy of LNP023 in patients with a kidney disorder called IgAN nephropathy
- Primary IgA Nephropathy br>MedDRA version: 20.0 Level: HLGT Classification code 10029149 Term: Nephropathies System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Argentina, Australia, Belgium, China, Denmark, Finland, Germany, Korea, Republic of, Netherlands, Norway, Singapore, Sweden, Taiwan, Thailand, United Kingdom, United States
- 2017-11-23
Authorised
- A study evaluating the of safety and efficacy of LNP023 in patients with a kidney disorder called IgAN nephropathy
- Primary IgA Nephropathy br>MedDRA version: 20.0 Level: HLGT Classification code 10029149 Term: Nephropathies System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Argentina, Australia, Belgium, China, Denmark, Finland, Germany, Korea, Republic of, Netherlands, Norway, Singapore, Sweden, Taiwan, Thailand, United Kingdom, United States
- 2017-10-17